Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cindy Delbrook"'
Autor:
David F. Stroncek, Pamela L. Wolters, Terry J. Fry, Maryalice Stetler-Stevenson, Haneen Shalabi, Cindy Delbrook, Crystal L. Mackall, Staci Martin, Nirali N. Shah, Daniel W. Lee, Eva H. Baker, Seth M. Steinberg, Bonnie Yates, Constance M. Yuan
Publikováno v:
J Clin Oncol
PURPOSE CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but relapse rates are high. The role for allogeneic hematopoietic stem-cell tr
Autor:
Staci Martin, Maryalice Stetler-Stevenson, Sandhya R. Panch, Seth M. Steinberg, Steven L. Highfill, Haris Qureshi, Cindy Delbrook, Haiying Qin, Alina Dulau-Florea, Hao-Wei Wang, Crystal L. Mackall, Jianjian Jin, Constance M. Yuan, Lauren Little, Pamela L. Wolters, David F. Stroncek, Haneen Shalabi, Leah Hoffman, Dalia Salem, Terry J. Fry, Nirali N. Shah, Anusha Ponduri, Minh Tran, Bonnie Yates, Amanda K. Ombrello
Publikováno v:
J Clin Oncol
PURPOSE Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy.
Publikováno v:
Journal of Clinical Oncology. 32:10075-10075
10075 Background: Childhood melanoma is rare with an incidence of ~300 cases/yr in the United States. Stage IV disease is detected in 1-10% of reported pediatric melanomas. The treatment of this ch...
Autor:
James N. Kochenderfer, Dave Stroncek, Daniel Warnell Lee, Marianna Sabatino, Alan S. Wayne, Steven A. Rosenberg, Nirali N. Shah, Kelly Richards, Maryalice Stetler-Stevenson, Crystal L. Mackall, Cindy Delbrook
Publikováno v:
Journal of Clinical Oncology. 31:10008-10008
10008 Background: Despite intensive chemotherapy and HSCT, outcomes in relapsed/refractory pediatric B cell ALL and NHL are poor. To treat children with or without prior allogeneic-HSCT and quickly deliver therapy, we developed a Phase I trial of 19C